Adial Pharmaceuticals (ADIL) vs Senti Biosciences (SNTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Adial Pharmaceuticals (ADIL) has outperformed Senti Biosciences (SNTI) over the past year, losing 60.3% versus a loss of 81.9%. Over five years, SNTI leads with a -99.7% price change compared with -99.8% for ADIL. Adial Pharmaceuticals is the larger company by market cap ($10.4 million vs $10.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADIL | SNTI |
|---|---|---|
| Share price | $3.97 | $0.3217 |
| Market cap | $10.42M | $10.02M |
| 1-day change | -0.50% | -2.52% |
| YTD return | -27.82% | -69.07% |
| 1-year return | -60.30% | -81.93% |
| 5-year return | -99.84% | -99.68% |
| EPS (TTM) | $-20.65 | $-1.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.50 | $2.88 |
| 52-week low | $1.31 | $0.29 |
| Distance from 52-week high | -62.19% | -88.83% |
| Analyst consensus | none | none |
| Avg. price target upside | +109.82% | +4096.46% |
| Average volume | 56.16K | 573.78K |
| Shares outstanding | 2.63M | 31.15M |
| Employees | 5 | 39 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADIL has outperformed SNTI by 21.6 percentage points over the past year.
About Adial Pharmaceuticals
ADIL stock →Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder.
Healthcare · Biotechnology · 5 employees
About Senti Biosciences
SNTI stock →Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
Healthcare · Biotechnology · 39 employees
ADIL vs SNTI FAQ
Which is bigger, Adial Pharmaceuticals or Senti Biosciences?
Adial Pharmaceuticals (ADIL) is larger, with a market capitalization of $10.42M compared with $10.02M for Senti Biosciences (SNTI).
Which stock has performed better over the past year, ADIL or SNTI?
ADIL returned -60.30% over the past 12 months, compared with -81.93% for SNTI (price return, excluding dividends). Past performance does not predict future results.
Are Adial Pharmaceuticals and Senti Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.